GlassScriptPhysician profile
Muhammad Khokhar
NPI 1780979963
$1,714.85
in general payments reported to CMS, 2019-2025
29 companies · $711 in 2025
The $711 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.26 · 2022: $121 · 2023: $305 · 2024: $514 · 2025: $711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304 · Consulting Fee: $200 · Education: $26.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,304.08 |
| Consulting Fee | $200.00 |
| Education | $26.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $224.86 | 2022-2024 | |
| Celgene Corporation | $180.04 | 2022-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $140.30 | 2022-2025 | |
| Pfizer INC. | $129.54 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $113.95 | 2023-2025 | Keytruda, Keytruda Qlex |
| Genzyme Corporation | $101.83 | 2023-2025 | |
| Beigene USA, INC. | $73.15 | 2022-2024 | Brukinsa |
| Agios Pharmaceuticals, INC. | $68.80 | 2025 | Pyrukynd |
| Lilly USA, LLC | $62.17 | 2022-2025 | Jaypirca, Verzenio |
| Eisai INC. | $61.92 | 2023-2025 | |
| Janssen Biotech, INC. | $47.03 | 2022-2025 | Rybrevant, Akeega, Erleada |
| Array Biopharma INC | $46.51 | 2025 | Lorbrena, Braftovi, Mektovi |
| Genentech USA, INC. | $42.23 | 2019-2024 | Polivy |
| Bayer Healthcare Pharmaceuticals INC. | $42.10 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $39.94 | 2025 | Enhertu, Tagrisso |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.32 | 2025 | Fruzaqla |
| Janssen Scientific Affairs, LLC | $30.91 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $30.40 | 2025 | Onivyde |
| Seagen INC. | $26.22 | 2023 | Adcetris |
| Exelixis INC. | $25.04 | 2024 | Cabometyx |
| Astellas Pharma US INC | $23.45 | 2023 | Xtandi |
| Madrigal Pharmaceuticals | $22.72 | 2025 | Rezdiffra |
| Amgen INC. | $19.67 | 2023 | Lumakras |
| Inari Medical, INC. | $19.39 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Glaxosmithkline, LLC. | $18.70 | 2022 | |
| Springworks Therapeutics, INC. | $17.35 | 2024 | Ogsiveo |
| Beone Medicines USA, INC. | $17.31 | 2025 | Tevimbra |
| Emd Serono, INC. | $16.73 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Khokhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.